Recently an association between @entity0 and @entity32 has emerged as the seventh hallmark of @entity5 . @entity32 is a key contributor in the development and progression of @entity105 . Inflammatory pathways play an important role in the causation of @entity0 . @entity1851 ( @entity1851 ) an acute-phase reactant inflammatory protein is synthesized in hepatocytes in response to cytokines that are released from leucocytes within the @entity5 microenvironment. Several epidemiological studies appraised an association of @entity1851 with @entity0 risk with inconsistent findings. Elevated levels at the time of diagnosis of @entity0 indicate @entity146 . @entity1851 is also a well-established independent prognostic marker. @entity0 survivors with the state of chronic @entity32 are at risk of recurrence and @entity209 . @entity1851 lowering agents along with chemotherapeutic drugs will improve the survival of @entity0 @entity1 . Also, it is a risk predictor for subsequent @entity1370 in @entity1 receiving chemotherapy. The present review is aimed at elucidating the role of @entity1851 , as an inflammatory risk marker and prognostic predictor of @entity0 . It also focuses on conflicting views on the role of @entity1851 in @entity0 and its impact on therapeutic interventions.

XXXX and Breast Cancer: New Insights from Old Molecule.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'Chronic inflammation'] @entity0 :: ('MESH:D001943', 'Disease') :: ['Breast cancer', 'breast cancer'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressiveness of the tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic disturbances'] @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis'] @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiotoxicity'] @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']
@entity1851 :: (1401,Gene) :: ['C-Reactive Protein']
